Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections

Overview of attention for article published in AAPS Open, April 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

news: 2 news outlets

twitter: 13 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 3 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 1 citation of this research output.

1

The most recent citing publication is shown below. View this citation on Dimensions.

Niclosamide: A career builder PART I: (Almost) Everything You Wanted To Know About Niclosamide But Were Too Afraid To Ask PART II: Nanomedicines? A Carrier-Free Nanomedicine for Cancer and a Simple Buffered Solution to Prevent COVID19 and Other Respiratory Infections: They Just Need Testing Invited Manuscript: J Controlled Release VSI in Honor of Prof. Park

Article in Journal of Controlled Release (March 2024)